XML 65 R51.htm IDEA: XBRL DOCUMENT v3.23.2
License Agreements - Syros (Details)
$ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2018
USD ($)
item
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
License Agreements            
Fair market long term investments   $ 170,316   $ 170,316   $ 133,676 [1]
Unrealized gain (loss) on long term investments   $ 41,811 $ (24,897) $ 36,493 $ (71,482)  
Syros Pharmaceuticals, Inc.            
License Agreements            
Common stock held from investment (in shares) | shares   0.1   0.1    
Fair market long term investments   $ 300   $ 300   $ 300
Unrealized gain (loss) on long term investments   $ 0 $ (200) $ (100) $ (2,200)  
Syros Pharmaceuticals, Inc.            
License Agreements            
Number of program targets | item 7          
Syros Pharmaceuticals, Inc. | Maximum            
License Agreements            
Target selection and option exercise fee payment $ 54,000          
Syros Pharmaceuticals, Inc. | Maximum | Development and Regulatory Milestones            
License Agreements            
Additional milestone payments under the license agreement 50,000          
Syros Pharmaceuticals, Inc. | Maximum | Commercialization Milestones            
License Agreements            
Additional milestone payments under the license agreement $ 65,000          
[1] The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date.